ReviewFrontiers in medicine2026
CD147: a critical factor in normal and pathological pregnancies.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD147 (Basigin/EMMPRIN) is a widely expressed trans-membrane glycoprotein. While its role in tumorigenesis is well-established, its functions in the process of pregnancy remain to be systematically elucidated. This review summarizes the expression patterns and functional mechanisms of CD147 in both normal and pathological pregnancies. During normal pregnancy, CD147 plays a critical role in embryo implantation, placental development, and pregnancy maintenance by regulating the expression of matrix metalloproteinases (MMPs), promoting angiogenesis, participating in the construction of the maternal-fetal immune micro-environment, and modulating placental energy metabolism. In pathological pregnancies, aberrant CD147 expression is closely associated with various obstetric complications: its down-regulation is linked to pre-eclampsia, recurrent implantation failure, and fetal growth restriction, whereas its up-regulation may promote invasive behaviors in gestational choriocarcinoma and placenta accreta spectrum. This review emphasizes the "dual regulatory" characteristic of CD147 in pregnancy, highlighting its potential as a biomarker and therapeutic target, and proposes directions for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.